Last updated: March 9, 2026
What is NDC 51672-4012?
NDC 51672-4012 is the prescription drug Nivolumab (Opdivo), a programmed death-1 (PD-1) immune checkpoint inhibitor manufactured by Bristol-Myers Squibb. It is approved for multiple oncology indications, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and others.
Market Overview
Market Size and Growth
The global oncology drug market was valued at approximately USD 185 billion in 2022 [1]. Immuno-oncology (IO) therapies, led by checkpoint inhibitors such as nivolumab, have experienced rapid growth due to expanded indications and improved outcomes.
Key Market Drivers:
- Expanding indications for nivolumab across multiple cancer types.
- Increasing adoption in combination therapies.
- Growing prevalence of target cancers globally.
Recent Data:
- The U.S. NSCLC market, a primary driver for nivolumab, was valued at USD 1.8 billion in 2022, with projections to reach USD 2.4 billion by 2026 [2].
- The melanoma segment is worth over USD 1 billion in the U.S. and Europe.
Competition
Major competitors include pembrolizumab (Keytruda), atezolizumab (Tecentriq), durvalumab (Imfinzi), and cemiplimab (Libtayo).
Market Share (2022):
| Drug |
Estimated US Market Share |
Indications |
| Nivolumab |
~30% |
Multiple cancers |
| Pembrolizumab |
~40% |
Broadest indication portfolio, higher penetration |
| Atezolizumab |
~15% |
Lung, bladder, breast |
| Durvalumab |
~10% |
Lung, bladder |
Pricing Context
Pricing for nivolumab varies by indication, region, and dosing frequency. In the U.S., average list prices for nivolumab monotherapy hover around USD 14,000 per month. The cost for a standard treatment course (e.g., 4 cycles) can exceed USD 55,000 [3].
Price Projections
Current Pricing Dynamics
- In U.S.: USD 14,000–USD 15,000 per month per patient.
- In Europe: Pricing is generally 20%–30% lower due to health system negotiations.
- In emerging markets: Prices can fall below USD 10,000 monthly, driven by market access strategies.
Future Trends
- Market Expansion: As indications expand (e.g., adjuvant lung cancer, early-stage melanoma), treatment durations may increase, maintaining or raising price points.
- Biosimilars: No biosimilars for nivolumab have entered the market yet; patent protections expire around 2028–2030, which could introduce competition and pressure prices downward.
- Pricing Strategies: Manufacturers may adopt value-based pricing to secure reimbursement in cost-conscious healthcare systems, potentially leading to discounts or performance-based agreements.
Price Forecast for 2025-2030
| Year |
Estimated Average Price (USD/month) |
Notes |
| 2023 |
USD 14,500 |
Current market price |
| 2025 |
USD 13,000–USD 14,500 |
Slight decrease due to market competition, increased biosimilar threat in late 2020s |
| 2030 |
USD 11,000–USD 13,000 |
Biosimilar entries may pressure prices, but expanded indications could offset volume declines |
Market Drivers for Price Stability
- Expansion into early-stage cancers, increasing treatment duration.
- Use in combination regimens, which may command premium pricing.
- Adoption in emerging markets with targeted pricing strategies.
Regulatory and Policy Influences
- Price negotiations with payers in high-income countries reduce net prices.
- Policy shifts favoring biosimilars could lead to price erosion.
- Inclusion in national formularies influences access and pricing.
Opportunity and Risks
Opportunities
- Growing global oncology markets.
- New indications, such as adjuvant settings.
- Potential combination therapies that command higher prices.
Risks
- Patent expiration leading to biosimilar competition.
- Increased price pressures from healthcare payers.
- Stringent regulatory and reimbursement policies.
Key Takeaways
- Nivolumab holds a significant market share within immuno-oncology, with sustained growth driven by multiple approved indications.
- U.S. list prices are approximately USD 14,000 per month, with international variations.
- Patent expiration and biosimilar market entry are primary risks to future pricing.
- Prices are projected to decline modestly through 2030, but expanded indications and combination regimens may stabilize or increase revenue streams.
- Market competition remains intense, with pembrolizumab as the primary rival.
FAQs
Q1: When will biosimilars for nivolumab become available, and how will they affect prices?
A1: Biosimilars are expected around 2028–2030, potentially reducing net prices by 20%–40% upon entry.
Q2: Which indications drive the highest revenue for nivolumab?
A2: Non-small cell lung cancer, melanoma, and renal cell carcinoma generate the majority of sales.
Q3: How are pricing negotiations conducted in different regions?
A3: The U.S. relies on payers and pharmacy benefit managers; Europe employs national negotiations; emerging markets often negotiate directly with manufacturers.
Q4: Are there any recent label expansions for nivolumab?
A4: Yes, recent approvals include adjuvant melanoma and combination therapies, which may influence pricing and market penetration.
Q5: What are the primary risks to future revenue growth?
A5: Patent expiry, biosimilar competition, regulatory restrictions, and payer pressure.
References
- Market Research Future. (2022). Oncology Drugs Market Size, Share & Trends.
- IQVIA. (2022). U.S. Oncology Market Data.
- SSR Health. (2022). U.S. Oncology Drug Pricing Report.
- Bristol-Myers Squibb. (2022). Opdivo Pricing and Indications Updates.
